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Summary
BACKGROUND: Hepatitis C virus (HCV) infections in
Switzerland are mainly related to intravenous drug use.
Since 2017, all patients with chronic hepatitis C can be
treated with direct-acting antivirals (DAAs) irrespective of
fibrosis stage. In March 2019, the Federal Office of Public
Health (FOPH) published guidelines for HCV manage-
ment in people who use drugs. To achieve HCV elimina-
tion by 2030, 80% treatment uptake is necessary.
AIM: To evaluate the benefit of interferon-based and in-
terferon-free HCV treatment in patients on opioid agonist
therapy (OAT) and monitor HCV elimination, a 2-year
study commissioned by the FOPH and conducted within
the Swiss Association for the Medical Management in
Substance Users (SAMMSU) cohort was performed.
METHODS: Since 2014, the SAMMSU cohort has recruit-
ed OAT patients from eight different centres throughout
Switzerland. In addition to yearly follow up, cross-sectional
data were collected at the time-points 1 May 2017, 1 May
2018 and 1 May 2019. HCV treatment uptake, adherence
and success, as well as reinfection rates, the effect of ear-
ly versus late treatment and the efficacy of the “treatment-
as-prevention” approach were analysed.
RESULTS: Between 1 May 2017 and 1 May 2019, the
number of patients enrolled into the SAMMSU cohort in-
creased from 623 to 900: 78% were male, the median age
was 45 years, 81% had ever used intravenous drugs, 13%
were human immunodeficiency virus (HIV) positive and
66% were HCV antibody positive. HCV treatment up to
2012 was exclusively interferon based (maximum 21 pa-
tients/year) and since 2016 exclusively interferon free (102
patients in 2017). Treatment success increased from 57%
(112/198; interferon based) to 97% (261/268; interferon
free) irrespective of cirrhosis or prior non-response to in-
terferon. Simultaneously, treatments became shorter and
better tolerated in the interferon-free era, resulting in few-
er preterm stops (17% vs 1%) and adherence problems
(9% vs 2%). Between 2015 and 2018, the proportion of
patients with no/mild fibrosis (F0/F1) at first HCV treatment
increased from 0% to 61%. Earlier treatment reduced the
duration of infectiousness. Between 1 May 2017 and 1
May 2019, the proportion of chronic hepatitis C patients
ever treated increased from 62% (198/321) to 80% (391/
490). In parallel, the HCV-RNA prevalence among HCV
antibody-positive patients declined from 36% (139/385) to
19% (113/593). The reinfection rate after successful treat-
ment was 2.7/100 person-years. The number of HCV first
diagnoses per year decreased from >20 up to 2015 to <10
in 2017 and 2018.
CONCLUSION: With nearly 100% DAA treatment success
and a low reinfection rate, treatment uptake directly trans-
lates into a reduction of HCV-RNA prevalence. Eighty per-
cent treatment uptake is feasible in OAT patients, and
adherence and treatment success are not worse than in
other populations. Duration of infectiousness and thus
HCV transmission can be reduced by early detection and
treatment of chronic hepatitis C.
Introduction
Hepatitis C is a blood-borne viral infection, which is highly
prevalent among persons who inject drugs (PWID) as a re-
sult of the common use of injection material (needle, sy-
ringe, filter, spoon, water) [1]. Hepatitis C virus (HCV)
transmission also occurs if snorting straws for intranasal
drug use are shared [2, 3]. Although about 25% of HCV in-
fected people spontaneously clear the virus, the remaining
75% develop chronic infection [4]. Presenting mostly with
unspecific symptoms slowly appearing over years, such as
fatigue, joint pain and neurocognitive disorders, hepatitis
Correspondence:
Andrea Bregenzer, MD,
MSc, Department of Infec-





Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 1 of 15
C may remain undetected for years and become a “silent
killer” [5]. About 20% of chronically infected individuals
develop liver cirrhosis after 20 years [6], with an annual
risk of hepatocellular carcinoma of 1–5% and of hepatic
decompensation of 3–6%. After an episode of decompen-
sation, the risk of death in the following year is 15–20%
[7]. In addition, hepatitis C is associated with an elevated
non-liver-related mortality [8].
Globally, there are 15.6 million PWID, with 52.3% being
HCV antibody positive [9]. The HCV antibody prevalence
in Switzerland is 0.7% in the general population [10],
26-48% in oral opioid agonist therapy (OAT) programmes
and 60–80% in heroin substitution programmes [11]. Of
the 22,000–27,000 opioid addicts in Switzerland [12],
about 80% are cared for in OAT programmes (oral OAT:
18,000; heroin: 1600) [13]. In about 60%, OAT is pre-
scribed by a general practitioner (GP) [13]. About 27%
of Swiss OAT patients have ongoing intravenous drug use
(IDU) [14].
In view of the highly effective and well tolerated pangeno-
typic interferon-free direct-acting antiviral (DAA) treat-
ments available [15–18], access to diagnosis, care and
treatment has become the main challenge in chronic he-
patitis C management. Early diagnosis and successful
treatment of chronic hepatitis C prevents HCV-related
complications and extrahepatic manifestations (individual
benefit), as well as further transmission (“Treatment as
Prevention; TasP)” [19] (social benefit).
Both the World Health Organization (WHO) and the Swiss
Hepatitis Strategy aim at HCV elimination by the year
2030 [20, 21]. In order to reach this goal, 80% treatment
uptake is necessary [20]. The “National Addiction Strategy
2017–2024” aims to reduce premature deaths due to ad-
diction [22]. This includes prevention and treatment of in-
fectious diseases such as hepatitis C. Since May 2017,
PWID and since October 2017, all patients with chronic
hepatitis C in Switzerland can be treated with DAAs ir-
respective of liver fibrosis stage [23, 24]. Before, reim-
bursement restrictions withheld DAA treatment from two
thirds of patients with chronic hepatitis C, i.e., those with
no or only mild fibrosis (F0/F1) [25]. Due to the high costs
(CHF 30,706.20 for 8 weeks of Maviret® [glecaprevir/pi-
brentasvir] and CHF 30,952.20 for 12 weeks of Epclusa®
[sofosbuvir/velpatasvir] http://www.spezialitätenliste.ch/
ShowPreparations.aspx), only infectious disease special-
ists, gastroenterologists and addiction specialists with ex-
perience in HCV treatment (http://www.bag.admin.ch/sl-
ref) are allowed to prescribe DAAs in Switzerland. In
March 2019, the Federal Office of Public Health (FOPH)
published guidelines for HCV management in drug users
[26].
Since 2014, the Swiss Association for the Medical Man-
agement in Substance Users (SAMMSU)-cohort
(http://www.sammsu.ch/cohort-database.html) has recruit-
ed OAT patients from eight different centres throughout
Switzerland [27].
To evaluate the benefit of interferon-based and interferon-
free HCV treatment in OAT patients and monitor HCV
elimination, a 2-year study commissioned by the Swiss
FOPH and conducted within the SAMMSU cohort was
performed between 2017 and 2019. HCV treatment uptake,
adherence and success, as well as reinfection rates, the ef-
fect of early versus late treatment and the efficacy of the
“treatment-as-prevention” approach were analysed.
Materials and methods
Ethical considerations
The SAMMSU cohort was approved by the ethics com-
mittees of all participating centres (leading ethical commit-
tee: St Gallen, EKSG 13/144). All participants gave writ-
ten informed consent. Data are stored and analysed in an
anonymised way.
Patient recruitment and data collection
SAMMSU cohort database
The SAMMSU cohort is an open cohort, which has, since
2014, recruited current or former drug users >18 years old
in all parts of Switzerland. Participants must have been in
an OAT programme for at least one day. There are no ex-
clusion criteria. During routine clinical care or on HCV ac-
tion days, patients of the eight currently participating cen-
tres (Aarau, Basel, Bern, Geneva, Lausanne, Lugano, St
Gallen and Zurich) are contacted by study nurses/physi-
cians. Both centralised and decentralised OAT settings are
represented, i.e., specialised OAT programmes with inte-
grated somatic care (led by a psychiatrist, somatic physi-
cian on-site) as well as patients receiving their OAT via the
general practitioner (GP).
In contrast to the Swiss Hepatitis C Cohort Study (SCCS)
[28], which enrols only HCV-positive patients, and the
Swiss HIV Cohort Study (SHCS) [29], which enrols only
human immunodeficiency virus (HIV)-positive patients,
the SAMMSU cohort also recruits both HCV- and HIV-
negative individuals.
At enrolment and thereafter at yearly intervals, study nurs-
es/physicians of each centre enter sociodemographic and
medical data into an electronic questionnaire, including in-
formation about drug use / risk behaviour, comorbidities,
medication, HCV treatment, diagnostic tests (e.g., liver
biopsy, Fibroscan®, abdominal sonography), vaccinations
and laboratory values. Every study nurse/physician has a
personal password-protected account and can only edit da-
ta of her/his own centre. At first data entry, every patient
gets a unique ID consisting of two letters for the centre and
a five-digit consecutive number. Every centre maintains its
own code list. The web-based central database was estab-
lished with SecuTrial® and is maintained by the Clinical
Trial Unit of the University Basel. For this study, a data-
base extract from 2 September 2019 was used.
Cross-sectional survey at the patient level
To evaluate the effect of the abrogation of the DAA re-
imbursement restrictions for PWID on HCV treatment up-
take, two cross-sectional surveys at the patient level were
conducted one and two years after the 1 May 2017. This
also allowed three point-prevalence measurements regard-
ing HCV antibody and HCV-RNA positivity (1 May 2017,
1 May 2018, 1 May 2019).
Cross-sectional survey at the centre level
To evaluate if patients enrolled into the SAMMSU cohort
are representative for the Swiss population of OAT patients
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and to describe the OAT settings on the 1 May 2017, 1 May
2018 and 1 May 2019, the SAMMSU centres received
an additional centre questionnaire in May 2018 and May
2019.
The questionnaires for the cross-sectional surveys at pa-
tient and centre level were collectively developed by the
study physicians and are presented in appendices 2 and 3,
respectively.
Definitions
New HCV infection: first detection of HCV antibodies
(first diagnosis), irrespective of the time-point of infection.
HCV reinfection: first detection of HCV-RNA after spon-
taneous clearance or successful treatment.
Spontaneous clearance/elimination: HCV-RNA becomes
persistently undetectable without treatment.
Chronic hepatitis C: HCV-RNA persistence 6 months after
new infection or reinfection.
HCV treatment uptake: proportion of patients with chronic
hepatitis C ever treated.
Treatment success = sustained virological response (SVR):
12 or 24 weeks after HCV treatment no HCV-RNA de-
tectable.
Preterm treatment stop: treatment stop before the intended
treatment duration has been completed.
Adherence: assessment by the treating physician (SAMM-
SU cohort: adherence problems during treatment: yes/no;
cross-sectional survey at the patient level: excellent/mod-
erate/bad).
Adherence-supporting measures: directly observed thera-
py (DOT) ≥5×/week, weekly dispensing of the HCV med-
ication in a pill box.
Duration of infectiousness: first intravenous drug use
(IDU) as potential time-point of infection until first HCV
treatment.
Liver fibrosis stage according to Fibroscan®: F0/F1 (no/
mild fibrosis): ≤7.0 kPa; F2 (significant fibrosis): >7.0 kPa
and ≤9.5 kPa; F3 (severe fibrosis): >9.5 kPa and ≤12.5
kPa; F4 (cirrhosis): >12.5 kPa [30, 31]
Statistical analysis
Categorical variables were compared with the chi-square
and the Fisher’s exact tests. Continuous variables were
analysed with the Wilcoxon rank-sum test (unpaired data).
A two-sided p-value <0.05 was considered significant.
Time-to-event analyses: For the primary HCV infection
rate, the observation time was from the first IDU to HCV
first diagnosis (first positive HCV antibody test) or the last
negative HCV antibody test for patients remaining HCV
antibody negative. For the HCV re-infection rate after suc-
cessful treatment, the observation time was from the end
of treatment until the patients became HCV RNA positive
again or the last negative HCV RNA for patients remain-
ing HCV RNA negative.
Test-frequency analyses: Observation time was one year
prior to registration until the last follow up.




On 1 May 2017, 1 May 2018 and 1 May 2019, 623, 757
and 900 patients, respectively, were enrolled in the
SAMMSU cohort. This is a yearly increase of 22% (134
patients) and 19% (143 patients). There was no significant
change in the baseline characteristics at registration over
time. Of the 900 patients registered by 1 May 2019, 87%
were male, the median age was 45 years at registration and
20 years at first IDU, 81% reported ever using intravenous
drugs and 89% ever using intranasal drugs, 13% were HIV
positive (99% ever HIV treatment) and 66% HCV anti-
body positive. Of the 457 patients with chronic hepatitis C,
59% had already been treated at least once at registration
(table 1).
Of the 900 SAMMSU patients, 80.6% (725) were from the
German-speaking part of Switzerland (Aarau, Basel, Bern,
St Gallen, Zurich), 6.4% (58) from the French-speaking
part (Geneva, Lausanne) and 13.0% (117) from the Italian-
speaking part (Lugano). At 40.8%, the biggest proportion
of patients came from the SAMMSU centre Aarau, fol-
lowed by Zurich (18.4%), Lugano (13.0%) and Basel
(11.9%). Centre-specific differences in the baseline char-
acteristics are described in table 1.
Centre/setting characteristics and representativeness
In Aarau, 58% (367/631) of all OAT patients in the canton
and 59% (75/128) of the heroin substitution programme in
Brugg were enrolled into SAMMSU. In Basel, 66% (41/
62) of the OAT patients of a private practice, 10% (19/199)
of the ADS (Ambulanter Dienst Sucht) and 15% (22/150)
of the heroin substitution programme Janus were recruited.
In Bern, 12% (22/190) of the patients of the heroin sub-
stitution programme KODA (Kontrollierte Drogenabgabe)
were enrolled. In Lausanne, 6% (24/415) of the POLADD
(Policlinique d’Addictologie, Département de Psychiatrie
du CHUV) patients and in Lugano, 13% (117/900) of the
OAT patients of the canton Ticino (no heroin substitution)
were recruited. In St Gallen, 48% (12/25) of the patients
of the methadone substitution programme of the Infectious
Diseases Outpatient Clinic of the Cantonal Hospital St
Gallen, 32% (23/72) of the MSH1 (heroin substitution pro-
gramme) and 4% (3/102) of the MSH2 (methadone sub-
stitution programme) were enrolled. In Zurich, 18% (159/
881) of the Arud patients in Zurich take part in SAMMSU,
but none of the 98 Arud patients in Horgen.
Heroin substitution programmes offer twice daily substitu-
tion 7 days/week, whereas institutions without heroin sub-
stitution are normally open only 5 days/week. The num-
ber of substitution patients ranges from 10 to 881 and the
yearly fluctuation rate is 12–37%. HCV and HIV antibody
rapid tests are routinely used in 5/13 institutions. So far,
capillary HCV-RNA measurement on dried blood spots is
established only in POLADD, Lausanne. Only 4/13 insti-
tutions offer sonography on site, whereas Fibroscan® is
available in 6 institutions. In four institutions, HCV ac-
tion days take place several times a year, where HCV/HIV
rapid tests, capillary HCV RNA quantification (GeneX-
pert®), Fibroscan®, sometimes sonography, venous blood
draw for hepatitis A and hepatitis B virus (HAV/HBV)
serology and HAV/HBV vaccination are offered on site.
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On 1 May 2019, on-site prescription of DAA treatments
was possible in only 7/13 institutions.
In the SAMMSU cohort, the proportion of patients with
unknown HCV serostatus is <1% (table 2). However, in
many institutions from which the SAMMSU patients were
recruited, it was 20–25% on 1 May 2018 and decreased
to 10–15% on 1 May 2019. The proportion of HCV an-
tibody-positive patients with unknown HCV-RNA status
was ≤10% in most institutions, but <5% in SAMMSU.
The proportion of HCV antibody-positive patients with
known HCV-RNA who had ever had chronic hepatitis C
was 60–80% in the source institutions, but 80% in SAMM-
SU. Between 1 May 2017 and 1 May 2019, HCV treatment
uptake has increased, but 80% or even 90% had not yet
been achieved in all institutions.
Differences between HCV antibody-positive and -nega-
tive persons
Patients already HCV antibody positive at registration
were about 8 years older (47 vs 39 years), their first IDU
was longer ago (25 vs 13 years) and the proportion who
had ever used intravenous drugs was almost twice as high
(96% vs 52%) (table 3). Besides, the proportions with on-
going IDU (27% vs 17%) and ever using cocaine and ben-
zodiazepines were higher in HCV antibody-positive pa-
tients. HIV positivity (18% vs 2%) and ever having a
syringe abscess (17% vs 3%) were more frequent. Over-
all, HCV antibody-positive patients were longer exposed,
had more frequent and more risky injections and had ben-


























































































































































































































































y = years; reg. = registration; IQR = interquartile range; IDU = intravenous drug use; HIV = human immunodeficiency virus; HCV = hepatitis C virus; CHC = chronic hepatitis C;
HAART = highly active antiretroviral therapy * For 98 of the 115 HIV patients on 1 May 2019, the year of the first HIV treatment was available. In 13% (13/98) it was before 1996,
i.e., in the pre-HAART era, and in 87% it was thereafter. At the registration visit, 96% (110/115) were currently under HIV treatment.

























































HCV = hepatitis C virus; CHC = chronic hepatitis C; SVR = sustained virological response * For some patients receiving HCV treatment, no check for SVR has taken place (lost
to follow-up between end of treatment and SVR check) and for many of the only recently treated patients, the time for SVR check has not been reached yet. In these cases, the
last available HCV-RNA measurement was used as a surrogate for HCV treatment success, even if it was the first HCV-RNA measurement under treatment or the check at the
end of treatment.
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efitted less from harm reduction (OAT, needle syringe pro-
grammes).
HCV treatment uptake and success
By 2 September 2019, 505 HCV treatments were docu-
mented in the SAMMSU cohort (405 first, 78 second, 17
third, 4 fourth and 1 fifth HCV treatments). Thirty-nine
percent (198) were interferon-based and 61% (307) inter-
feron-free (16 still ongoing). Up to 2012, HCV was treat-
ed exclusively with interferon-based treatments (maximum
21 patients/year) and since 2016 with exclusively interfer-
on-free treatment (102 patients in 2017; fig. 1).
Treatment success increased 1.7-fold (95% CI 1.5–2.0)
from 56.6% (112/198; 95% CI 49.6–63.3%; interferon-
based) to 97.4% (261/268; 95% CI 94.7–98.7%; interfer-
on-free; p <0.001; fig. 2). Prior non-response to interferon
(onetime or repeated) reduced the SVR rate for another in-
terferon-based, but not for interferon-free, treatment (fig.
2).
For 60% (242) of the 405 first HCV treatments, a Fi-
broscan® result was available before treatment (20 [8.3%]
interferon-based and 222 [91.7%] interferon-free treat-
ments). Median time between Fibroscan® and start of the
first HCV treatment was 90 days (IQR 42–231). With in-
terferon-free treatment, the SVR rate was ≥97% irrespec-
tive of fibrosis stage: F0/F1 97.6% (81/83), F2 100% (33/
33), F3 97.1% (33/34), F4 97.5% (39/40).
By 2 September 2019, there were 373 HCV treatments
with documented SVR in 362 patients. In 2017, when
DAA reimbursement restrictions were abrogated in
Switzerland, 87 SVRs were achieved, as many as in the
entire interferon era (86 SVRs between 1987 and 2012).
The proportion with “SVR after first treatment” among all
SVRs per year increased from 68.8% (33/48) in 2015 to
88.9% (48/54) in 2018 (p = 0.012).
Adherence
Compared with the interferon era, the proportion with
preterm treatment stop decreased in the interferon-free era,
from 17.2% (34/198, 95% CI 12.6–23.0%) to 0.7% (2/307,
95% CI 0.2–2.3%; p <0.001) and the proportion with ad-
herence problems from 8.6% (17/198, 95% CI 5.4–13.3%)
to 2.3% (7/307, 95% CI 1.1–4.6%; p = 0.001; fig. 3).
From 2016 onwards (interferon-free era), there were 201
HCV treatments in the cross-sectional data from seven
centres. In 97.9% (183/187) adherence was classified as
“excellent”, in 1.6% (3) as “moderate” and in 0.5% (1)
as “bad”. Overall, the SVR rate was 97.7% (171/175).
Table 3: Baseline characteristics of HCV antibody-positive and -negative patients (cohort data).
HCV antibody positive at reg.
(n = 613)
HCV antibody negative at reg. (n
= 326)


























































































Year of first IDU: (n = 559) (n = 160)
1970–1979 7.3% (41) 0.6% (1) 0.129 4.28 (0.55–33.17)
1980–1989 36.0% (201) 13.1% (21) 1.0 (ref.)
1990–1999 32.6% (182) 26.3% (42) 0.005 0.45 (0.26–0.80)
2000–2009 18.1% (101) 28.8% (46) <0.001 0.23 (0.13–0.42)
2010–2019 6.1% (34) 31.3% (50) <0.001 0.07 (0.03–0.15)
HCV = hepatitis C virus, reg. = registration, OR = odds ratio, CI = confidence interval, y = years, IQR = interquartile range, IDU = intravenous drug use, HIV = human immunode-
ficiency virus, ref. = reference
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All three patients with only moderate adherence achieved
SVR. In less than half of the treatments (45.1%, 78/173),
DOT was used to support adherence. One centre (Lugano)
used virtually no adherence-supporting measures (DOT
and weekly pill box in only 2.7%, 1/37) without a negative
effect on adherence (excellent in 100%, 35/35) and treat-
ment success (97.1%, 34/35 SVR).
Time-point of treatment and treatment success
Although cirrhotic patients can be treated with success
rates similar to those of patients with earlier stages of
fibrosis with interferon-free treatments (see above), the
time-point of treatment matters.
In the past, diagnosis and treatment of hepatitis C were de-
layed (fig. 4). The median time between the first IDU (sur-
rogate for the time of infection) and the first diagnosis of
HCV was 9 years (IQR 4–18; n = 539), and the median
time between the first IDU and the first HCV treatment 22
years (IQR 13–29; n = 378) – the time in which the patients
were infectious and could develop cirrhosis.
For 226 patients, the year of first IDU was known and a
Fibroscan® result available prior to the first HCV treat-
ment (HCV therapy start years 2007–2019). The median
duration of infectiousness in patients already cirrhotic at
the start of their first HCV treatment was 30 years (IQR
23–33; n = 51). In patients treated at earlier liver fibrosis
stages (F0–F3), the median duration of infectiousness was
25 years (IQR 16–31; n = 175; p = 0.020; fig. 5).
Between 2015 and 2018, the proportion of patients already
cirrhotic at first HCV treatment declined from 50% (15/30)
Figure 1: Number of interferon-based and interferon-free hepatitis C virus treatments per calendar year. IFN = interferon (status as of 2 Sep-
tember 2019, overall 942 SAMMSU patients).
Figure 2: Sustained virological response (SVR) rate after interferon-based and interferon-free HCV treatment, if outcome known (overall and
according to the number of prior HCV treatments). HCV = hepatitis C virus; IFN = interferon. * Once in combination with telaprevir and once in
combination with sofosbuvir (status as of 2 September 2019, overall 942 SAMMSU patients).
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Figure 3: Proportion of interferon-based and interferon-free HCV treatments with pre-term stop and adherence problems, respectively. HCV =
hepatitis C virus; IFN = interferon (status as of 2 September 2019, overall 942 SAMMSU patients).
Figure 4: Number of patients with first IDU, first diagnosis of HCV, first time positive for HCV-RNA and first HCV treatment per calendar year.
IDU = intravenous drug use; HCV = hepatitis C virus. Data at registration and follow-up (status as of 2 September 2019, overall 942 SAMMSU
patients).
Figure 5: Duration of infectiousness according to fibrosis stage at
first HCV treatment. Patients with Fibroscan® measurement before
the first HCV treatment and year of first intravenous drug use
known (n = 226, start year of first HCV treatment 2007–2019) (sta-
tus as of 2 September 2019, overall 942 SAMMSU patients). HCV
= hepatitis C virus. Liver fibrosis stage according to Fibroscan®:
F0/F1 (no/mild fibrosis) ≤7.0 kPa; F2 (significant fibrosis) >7.0 kPa
and ≤9.5 kPa; F3 (severe fibrosis) >9.5 kPa and ≤12.5 kPa; F4
(cirrhosis) >12.5 kPa.
to 13% (7/54; p <0.001) and the proportion of patients with
no or mild fibrosis at first HCV treatment increased from
0% (0/30) to 61% (33/54; p <0.001; fig. 6).
Treatment as prevention
At enrolment into the SAMMSU cohort, 95.7% (112/117)
of the HIV patients were under HIV treatment, with 94.0%
(109/116) having undetectable HIV-RNA (<50 cop/ml, i.e.,
untransmittable). At the reference dates 1 May 2017, 1
May 2018 and 1 May 2019, the HIV-RNA prevalence
(≥50 cop/ml) among the HIV positives was 6.7% (6/90),
5.7% (6/105) and 6.1% (7/114, 95% CI 3.0–12.1%), re-
spectively. Among all SAMMSU cohort patients (i.e., all
HIV positives and negatives), the HIV-RNA prevalence
was 1.0% (6/623), 0.8% (6/757) and 0.8% (7/900, 95% CI
0.4–1.6%) on the respective reference dates. Until 2002/
2003, up to eight patients yearly were newly diagnosed
with HIV, whereas in the eight years after 2011, there was
only one HIV first diagnosis, in 2015 (fig. 7).
Between 1 May 2017 and 1 May 2019, HCV treatment
uptake increased from 61.7% (198/321) to 79.8% (391/
490; table 2). In parallel, the HCV-RNA prevalence de-
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creased from 36.1% (139/385) to 19.1% (113/593; 95% CI
16.1–22.4%) among the HCV antibody-positive patients
and from 22.3% (139/623) to 12.6% (113/900, 95% CI
10.6–14.9%) among all SAMMSU cohort patients (i.e., all
HCV positives and negatives).
This development can also be seen in the cross-sectional
data of seven SAMMSU centres (fig. 8): the higher the
increase in treatment uptake the higher the decrease in
HCV-RNA prevalence among the HCV antibody-positive
patients. On the 1 May 2019, some centres had already
achieved >90% treatment uptake, which was associated
with a reduction of HCV-RNA prevalence to <10%. On
the 1 May 2019, the SAMMSU centre Aarau, with a high
proportion of patients cared for in a decentralised setting,
had a markedly lower rate (79.4%, 104/131; 95% CI
71.7–85.4%) than the other five centres taken together
(93.1%, 241/259; 95% CI 89.3–95.6%; p <0.001; supple-
mentary table S1 in appendix 1.
Reinfection risk
To calculate the rate of HCV first diagnosis, the year of
first IDU was available for 663 patients (total observation
time 8801.8 years, median observation time 11.8 years,
IQR 5.5–20.1, range 0.4–45.9). Between 1970 and 2019,
there were 518 HCV first diagnoses, resulting in an HCV
first diagnosis rate of 5.89 per 100 person-years (95% CI
5.40–6.41) and a cumulative HCV infection rate of 78.1%
(95% CI 74.8–81.1%).
To calculate the reinfection rate after successful treatment,
information on 280 patients with a total observation time
of 739.4 years was available (median observation time
1.1 years, IQR 0.4–3.2, range 0.003–29.1). From 1988 to
Figure 6: Distribution of fibrosis stage at first HCV treatment according to calendar year. Two hundred and forty-two first HCV treatments with
Fibroscan® measurement before treatment (start year of first HCV treatment 2007–2019) (status as of 2 September 2019, overall 942 SAMM-
SU patients). Liver fibrosis stage according to Fibroscan®: F0/F1 (no/mild fibrosis) ≤7.0 kPa; F2 (significant fibrosis) >7.0 kPa and ≤9.5 kPa;
F3 (severe fibrosis) >9.5 kPa and ≤12.5 kPa; F4 (cirrhosis) >12.5 kPa
Figure 7: Number of first diagnoses of HIV and HCV per calendar year. Data at registration (status as of 2 September 2019, overall 942
SAMMSU patients). HIV = human immunodeficiency virus; HCV = hepatitis C virus
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2019, there were 20 diagnoses of HCV reinfection after
successful treatment, resulting in a reinfection rate of 2.70
per 100 person-years (95% CI 1.75–4.19) and a cumulative
HCV reinfection rate of 7.1 per 100 treated patients (95%
CI 4.1–10.8).
Seventeen reinfections were observed in 88 patients re-
ceiving interferon-based treatment during a total obser-
vation time of 545.3 years, and 3 reinfections were ob-
served in 192 patients on interferon-free treatment during
a total observation time of 194.2 years. Thus, the rein-
fection rate after successful interferon-based and interfer-
on-free HCV treatment was comparable, at 3.12 (95% CI
1.94–5.01) versus 1.55 (95% CI 0.50–4.79) per 100 per-
son-years (p = 0.253), but the cumulative reinfection rate
was higher after interferon-based treatment at 19.3 (95%
CI 12.4–28.8) versus 1.6 (95% CI 0.5–4.5) per 100 treated
patients. The large difference between these cumulative
reinfection rates is explained by the time of observation,
since the median observation time was 5.06 years (IQR
2.63–8.07, range 0.025–29.07) after interferon-based treat-
ment, but only 0.57 years (IQR 0.26–1.56, range
0.003–4.33) after interferon-free treatment.
In the cross-sectional data, 35 reinfections were document-
ed in 33 patients. One third (12) were after spontaneous
clearance and two thirds (23) after successful treatment
(17 after interferon-based, 6 after interferon-free treatment;
fig. 9). In 46% (16/35), the reason for reinfection was un-
known. If known, it was unsafe IDU in 95% (18/19) and in
one case an HCV positive partner.
In the 11 patients with a first reinfection after spontaneous
clearance, the median time since HCV first diagnosis was
11.3 years (IQR 3.3–13.9). Four patients cleared the virus
spontaneously, whereas seven developed chronic hepatitis
C, of whom four have already been treated successfully.
In the 22 patients with a first reinfection after successful
treatment, the median time since the end of treatment was
3.3 years (IQR 1.1–5.1), i.e., 4.2 years (IQR 2.3–5.3) for
interferon-based treatment (n = 17) and 0.9 years (IQR
0.9–1.1) for interferon-free treatment (n = 5). Outcome af-
ter reinfection was not available for two patients. Among
Figure 8: hepatitis C virus (HCV) treatment uptake and HCV-RNA prevalence in seven of eight SAMMSU centres (cross-sectional data). HCV
treatment uptake = proportion of chronically HCV infected patients ever treated; HCV RNA prevalence = proportion of HCV antibody positive
patients who were HCV RNA positive.
Figure 9: Number of reinfections after spontaneous clearance and successful treatment (interferon-based and interferon-free) per calendar
year (cross-sectional data): 35 reinfections in 33 patients. IFN = interferon; SC = spontaneous clearance; SVR = sustained virological re-
sponse
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the remaining patients, 95% (19/20) developed chronic he-
patitis C, of whom 15 have already been retreated success-
fully.
Two patients experienced repeated reinfections (Patient 1:
chronic hepatitis C → treatment → 1st reinfection → spon-
taneous clearance → 2nd reinfection → chronic hepatitis
C → successful treatment; Patient 2: chronic hepatitis C →
treatment → 1st reinfection → chronic hepatitis C → treat-
ment → 2nd reinfection → chronic hepatitis C → success-
ful treatment).
Test frequency
The median HCV antibody test frequency in HCV anti-
body-negative patients (n = 89) with a median follow-up
time of 3.4 years (IQR 2.9–4.3) was every 1.9 years (IQR
1.4–2.9). In patients after spontaneous clearance (n = 30)
with a median follow-up time of 3.2 years (IQR 2.3–4.3),
the median HCV-RNA test frequency was every 1.8 years
(IQR 1.1–3.3), and in patients after successful treatment
(n = 7 3) with median follow-uptime of 3.4 years (IQR
2.3–4), every 1.4 years (IQR 0.8–2.2), i.e., slightly higher
than after spontaneous clearance (p = 0.062).
Discussion
Principal findings
With interferon-free DAA treatment, HCV treatment suc-
cess in OAT patients increased to almost 100%, irrespec-
tive of cirrhosis or prior non-response to interferon. With
shorter and better tolerated treatments, adherence was ex-
cellent (even in the absence of adherence-supporting mea-
sures) and preterm stops became rare. Between 1 May
2017 and 1 May 2019, HCV treatment uptake could be
increased to 80%, resulting in a reduction of HCV RNA
prevalence to <20% among the HCV antibody positive pa-
tients, who represent two thirds of the SAMMSU cohort.
Since DAA reimbursement restrictions were abrogated in
Switzerland in 2017, patients are treated at earlier fibrosis
stages, which results in a shorter duration of infectious-
ness. At 2.7/100 person-years, the reinfection rate after
successful treatment was low. The number of HCV first di-
agnoses per year decreased from >20 up to 2015 to <10 in
2017 and 2018. However, HCV transmission is still ongo-
ing, whereas HIV transmission has been virtually stopped
with universal ART.
Adherence and treatment-success
Prejudices that PWID are less adherent, have more side ef-
fects and less treatment success in the case of HCV treat-
ment persist stubbornly [32], although they were already
refuted in the era of interferon-based treatment [33–36]. In
our study, with interferon-free DAA treatment, adherence
problems and preterm stops declined to 2% and 1%, re-
spectively, irrespective of DOT [37]. In the C-EDGE CO-
STAR study (elbasvir/grazoprevir in OAT patients with
and without ongoing drug use), similarly high adherence
was observed [38]: 96% completed treatment and >97%
had an adherence >95%. Drug use at baseline and during
HCV treatment did not negatively influence adherence and
treatment success. In contrast, in the SIMPLIFY study (so-
fosbuvir/velpatasvir in patients with IDU in the past 6
months) [39], low adherence (<90%) was observed in one
third of the participants. It was associated with recent or
ongoing injection of stimulants (cocaine and/or other am-
phetamines), but did not negatively affect treatment out-
come [40]. Remarkably, SVR rates were not worse, even
when at least seven consecutive doses were missed [41].
Thus, 100% adherence is not necessary to prevent resis-
tance and consequent treatment failure.
In our study with interferon-free DAA treatment, the SVR
rate in those with known outcome was 97%, irrespective
of cirrhosis or prior non-response to interferon. In the Ger-
man Hepatitis C Registry, OAT patients achieved a com-
parably high per protocol SVR rate, which was not dif-
ferent from that in non-OAT patients (96% vs 95%, p =
0.464) [42]. However, OAT patients had a higher rate of
loss to follow-up between the end of treatment and SVR
(10% vs 4%, p <0.001), which might be explained by
a change of the healthcare setting, difficult venous ac-
cess and presumed cure given the high treatment efficacy
[43]. Since 78% of relapses post-treatment occur within 4
weeks, SVR4 can predict SVR12 with a positive predictive
value of 98% and a negative predictive value of 100% [44].
In settings with a high yearly fluctuation rate (up to 37% in
our study), SVR4 determination might reduce the propor-
tion of completed HCV treatments with unknown outcome
(8%, 23/291, of interferon-free treatments in our study).
Reinfection
The risk of reinfection and the high costs of retreatment
are often mentioned as a reason to withhold HCV therapy
from people with ongoing IDU. In our study (OAT pa-
tients, one quarter to one third with ongoing IDU), the
overall HCV reinfection rate was low (2.7/100 person-
years), with no difference between interferon-based and in-
terferon-free treatment (3.1 vs 1.6/100 person-years, p =
0.253). A recent meta-analysis (17 studies with interferon-
based, 19 studies with DAA treatment) showed a compa-
rable HCV reinfection rate of 3.8/100 person-years (95%
CI 2.5–5.8) among OAT patients. It was markedly lower
in OAT patients with no recent drug use than in people re-
cently injecting drugs (1.4 vs 6.2/100 person-years) [45].
As in our study, reinfection rates were comparable follow-
ing interferon-based and DAA treatment (5.4 vs 3.9/100
person-years). Interestingly, the German hepatitis C cohort
(GECCO) reported an overall reinfection rate of 1.9/100
person-years (95% CI 1.4–2.5) since 2014 [46]. Reinfec-
tion was less frequent in PWID than in men who have sex
with men (1.1 vs 9.0/100 person-years).
Mathematical models suggest an increased HCV reinfec-
tion incidence in the initial phase of treatment scale-up
[14]. However, with decreasing HCV-RNA prevalence, re-
infection incidence will decrease again. Actually, more
HCV reinfections were diagnosed in recent years in the
SAMMSU cohort, but >80% were after spontaneous clear-
ance or interferon-based treatment. Thus, this might partly
be explained by increased HCV-RNA testing as a result
of better treatment options (detection bias). Reinfection in-
cidence and probability of spontaneous clearance can be
underestimated if HCV-RNA testing frequency is too low
[47]. Spontaneous clearance of primary HCV infection oc-
curs in about 25%, but spontaneous clearance is more fre-
quent in reinfections after spontaneous clearance (83%)
[48]. In our study, 95% of the first reinfections after suc-
cessful treatment became chronic, compared with only
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64% after spontaneous clearance. Anyway, reinfections
can be treated as successfully as primary infections. To
shorten the duration of infectiousness, chronic hepatitis C
can be diagnosed early, i.e., if HCV-RNA decreases <2 log
U/ml 4 weeks after diagnosis (85% negative predictive val-
ue for spontaneous clearance) [49–51].
Since 95% of reinfections with a known cause were due
to unsafe IDU, patient information, sufficient OAT dosing
[52] and needle-syringe distribution coverage are impor-
tant [53].
“Treatment-as-prevention”
Mathematical models have shown that a substantial re-
duction of HCV-RNA prevalence cannot be achieved with
OAT and needle-syringe programmes alone, but treatment
uptake must be increased [54]. According to the WHO,
80% treatment uptake is necessary to succeed in HCV
elimination by 2030 [20]. In our study, 80% treatment up-
take has been achieved with interferon-free DAA treatment
and was associated with a reduction of HCV-RNA preva-
lence to 19% among HCV antibody-positive patients and
to 13% in the total SAMMSU cohort. Although the number
of HCV first diagnoses per year has declined both in our
study and according to FOPH data [55], HCV transmis-
sion is still ongoing, whereas HIV transmission has virtual-
ly been stopped with universal antiretroviral therapy [56].
For HIV, the UNAIDS 90-90-90-target (90% diagnosed,
90% treated, 90% virologically suppressed) [57] has been
achieved in the SAMMSU cohort: 99.7% were tested, 96%
of the HIV-positive patients were under antiretroviral ther-
apy, of whom 97% were virologically suppressed. This re-
sulted in an HIV-RNA prevalence of 6% among the HIV
positives and <1.0% in the total SAMMSU cohort.
A reduction in HCV-RNA prevalence to 1% in the SAMM-
SU cohort would require 98% HCV treatment uptake
(100% treatment success, 50% ever had chronic hepatitis
C). Besides, HCV is ~10 times more infectious than HIV
through blood-to-blood contact [58] and SAMMSU cohort
patients may be part of injection networks [59] with higher
HCV-RNA prevalence. Contact tracing may help to identi-
fy individuals not yet engaged in health care and harm re-
duction [60]. In a model study, a “treat your friends” strat-
egy was more effective than random treatment [59].
Generalisability and future strategies
Treating chronic hepatitis C in OAT patients needs an extra
effort. Since they frequently have other priorities and OAT
programmes are often exclusively led by psychiatrists, first
of all, they must be made aware of the better HCV treat-
ment options available. Referral to gastroenterologists / in-
fectious disease specialists for DAA prescription is often
unrewarding because these patients often have difficulty
keeping appointments. Additionally, difficult venous ac-
cess after long-term intravenous drug use complicates di-
agnosis. Thus, DAA reimbursement irrespective of liver
fibrosis stage does not automatically result in increased
HCV treatment uptake. Awareness campaigns, HCV treat-
ment on-site and capillary blood HCV antibody [25] and
RNA testing [61–64] helped to remove barriers to diagno-
sis and treatment.
How to bring HCV treatment to OAT patients differs be-
tween centralised and decentralised settings. In decen-
tralised settings with a low case-load, capillary HCV-RNA
quantification with the dried blood spot method [65] might
be an alternative to Xpert® HCV Viral Load Fingerstick
point-of-care testing [61–64]. Similarly in such settings,
the aspartate aminotransferase (AST)-to-platelet ratio in-
dex (APRI) score [APRI = (AST/upper limit of normal of
AST)/platelet count (G/l) × 100] can replace Fibroscan®
for non-invasive exclusion of liver cirrhosis. Both an APRI
score <1.0 [66] and Fibroscan® ≤12.5 kPa [30] have a neg-
ative predictive value of ~95% at a liver cirrhosis preva-
lence of 15% and 25%, respectively. In our study, chronic
hepatitis C patients starting their first HCV treatment in
2018 had a cirrhosis prevalence of 13%.
FOPH guidelines [26] recommend yearly HCV screening
of patients at risk (OAT, ongoing drug use [injecting and
non-injecting]), which has not been achieved yet in the
SAMMSU cohort. In Switzerland, new HCV diagnoses
must be reported to the cantonal physician, who also has to
review all OAT prescriptions every 1–2 years. Documenta-
tion of HCV status for each OAT patient and yearly HCV
screening reminders sent to the OAT prescriber/provider
(GP/pharmacy) within the already existing platform
www.substitution-online.ch could facilitate implementa-
tion of the FOPH guidelines and monitoring of HCV elim-
ination.
Unlike in Australia [67] and France [68], in Switzerland
GPs cannot prescribe DAA. The HepCare-project, initiated
by the Swiss Hepatitis Strategy in spring 2019, allows
HCV treatment on the site of OAT provision (GP/psychi-
atrist). In a randomised controlled trial in Australia, treat-
ment uptake was higher in the GP than the hospital setting
(75% vs 35%), whereas treatment success was comparable
[43]. Increased retention in care halved the average cost of
treatment initiation [69].
Strengths and limitations
With almost 1000 patients in different OAT settings
throughout Switzerland, the SAMMSU cohort is a useful
tool for monitoring HCV elimination. Patients from Ger-
man- and Italian-speaking regions of Switzerland are over-
represented (81% vs 63% and 13% vs 8%, respectively),
whereas patients from French-speaking Switzerland are
underrepresented (6% vs 23%) [70]. Rhaeto-Romanic-
speaking Switzerland (0.5%) is not represented. Besides,
patients cared for in decentralised OAT settings (OAT via
GP or psychiatrist and pharmacy) are underrepresented,
not least because their recruitment and follow up is more
difficult. Since HCV management is better in centralised
than decentralised settings [25], and better inside than out-
side the cohort [71], HCV screening and treatment uptake
in the SAMMSU cohort is probably higher than in the gen-
eral Swiss OAT population.
Owing to a lack of manpower, in most centres only 5–20%
of the patients are enrolled into the SAMMSU cohort. Pa-
tients willing to be tested and treated are more likely to be
enrolled (enrolment bias), leading to an overrepresentation
of HCV antibody-positive patients, patients with chronic
hepatitis C and treated patients. HCV antibody-positive pa-
tients are older, the proportion with ever and ongoing IDU
is higher, their first IDU is longer ago and a higher pro-
portion are HIV positive. In contrast, unstable patients who
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are only a short time at one institution are less likely to be
enrolled. Thus, adherence might be overestimated.
So far, there are only a few reinfections after DAA treat-
ment and the follow-up time is still quite short. A longer
observation period is necessary to estimate the reinfection
rate after DAA treatment more reliably.
To counteract the delay of data entry resulting from only
yearly follow-up in the SAMMSU cohort, two cross-sec-
tional surveys 1 May 2018 and 1 May 2019 (1 and 2
years after the abrogation of DAA reimbursement restric-
tions for PWID) were performed. Since the study physi-
cian and/or the institution changed, the SAMMSU centre
Geneva could not contribute any cross-sectional data, and
Lausanne could only provide data in the first survey.
In the SAMMSU-cohort, 91% (445) of the 490 patients
who had ever had chronic hepatitis C had a Fibroscan®, but
only 27% (131) a liver biopsy (often many years ago).
Conclusion
With nearly 100% DAA treatment success and a low re-
infection rate, treatment uptake directly translates into a
reduction of HCV-RNA prevalence. Eighty percent treat-
ment uptake is feasible in OAT patients, and adherence and
treatment success are not worse than in other populations.
Duration of infectiousness and thus HCV transmission can
be reduced by early detection and treatment of chronic he-
patitis C.
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Appendix 1: Supplementary table
Table S1: HCV treatment uptake and HCV-RNA prevalence in seven of eight SAMMSU centres
1 May 2017 1 May 2018 1 May 2019
Aarau (n = 367)
Treatment uptake* 49.1% (57/116) 65.6% (80/121) 79.4% (104/131)
HCV-RNA prevalence† 48.3% (73/151) 34.0% (54/159) 20.2% (35/173)
Basel (n = 82)
Treatment uptake* 29.7% (19/64) 69.4% (43/62) 93.7% (59/63)
HCV-RNA prevalence† 66.7% (48/72) 31.9% (23/72) 8.3% (6/72)
Bern (n = 27)
Treatment uptake* 42.1% (8/19) 63.2% (12/19) 84.2% (16/19)
HCV-RNA prevalence† 50% (12/24) 41.7% (10/24) 21.7% (5/23)
Lausanne (n = 33)‡
Treatment uptake* 60.7% (17/28) 75% (21/28)
HCV-RNA prevalence† 43.3% (13/30) 33.3% (10/30)
Lugano (n = 111)
Treatment uptake* 74.0% (57/77) 92.2% (71/77) 96.1% (73/76)
HCV-RNA prevalence† 27.2% (25/92) 8.8% (8/91) 4.6% (4/87)
St Gallen (n = 46)
Treatment uptake* 54.8% (17/31) 93.3% (28/30) 92.9% (26/28)
HCV-RNA prevalence† 41.0% (16/39) 7.7% (3/39) 5.6% (2/36)
Zurich (n = 159)
Treatment uptake* 79.2% (42/53) 90.4% (66/73) 91.8% (67/73)
HCV-RNA prevalence† 21.1% (15/71) 10.1% (10/99) 8.0% (8/100)
Total (n = 825)
Treatment uptake* 55.9% (217/388) 78.3% (321/410) 88.5% (345/390)
HCV-RNA prevalence† 42.2% (202/479) 23.0% (118/514) 12.2% (60/491)
Total without Aarau (n = 458)
Treatment uptake* 58.8% (160/272) 83.4% (241/289) 93.1% (241/259)
HCV-RNA prevalence† 39.3% (129/328) 18.0% (64/355) 7.9% (25/318)
HCV = hepatitis C virus * In the case of chronic hepatitis C (currently HCV RNA positive or currently HCV RNA negative and ever treated); † among the HCV antibody positive
patients; ‡ no data for 1 May 2019 due to site interruption
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Appendices 2 and 3
SAMMSU-ID: ____________________ (please insert on all pages) 
1 
Questionnaire – Cross sectional study within SAMMSU May 2018 and May 2019 
How to enter not precisely known dates: 
If the day is unknown, enter “15/MM/YYYY”. If day and month are unknown, enter “15/07/YYYY”. 
1) On the reference date, what was the patient’s HCV-antibody- and HCV-RNA-status?





1a)-1d) The same values might appear more than once (i.e. “first …” and “last …” may be on the 
same date or tests may not have been repeated between the reference dates, respectively). 
a) if HCV-antibody-neg.(0), last neg. HCV-antibody-test before the respective date:
1.5.2017: ____/____/________ (DD/MM/YYYY) 
1.5.2018: ____/____/________ (DD/MM/YYYY) 
1.5.2019: ____/____/________ (DD/MM/YYYY) 
b) if HCV-antibody-pos.(1), first pos. HCV-antibody-test: ____/____/________ (DD/MM/YYYY)
if applicable  first pos. HCV-RNA-test after diagnosis: ____/____/________ (DD/MM/YYYY) 
if applicable    first neg. HCV-RNA-test after diagnosis: ____/____/________ (DD/MM/YYYY) 
(To determine the duration of infectiousness, please also give the first neg. HCV-RNA-test after a 
first pos. HCV-RNA-test, i.e. after spontaneous clearance or under successful treatment.) 
c) if HCV-antibody-pos.(1)/HCV-RNA-neg.(0), last neg. HCV-RNA before the respective date:
1.5.2017: ____/____/________ (DD/MM/YYYY) 
1.5.2018: ____/____/________ (DD/MM/YYYY) 
1.5.2019: ____/____/________ (DD/MM/YYYY) 
d) if HCV-antibody-pos.(1)/HCV-RNA-pos.(1), last pos. HCV-RNA before the respective date:
1.5.2017: ____/____/________ (DD/MM/YYYY) 
1.5.2018: ____/____/________ (DD/MM/YYYY) 
1.5.2019: ____/____/________ (DD/MM/YYYY) 
2) On the reference date, was the patient ever treated for hepatitis C?





SAMMSU-ID: ____________________ (please insert on all pages) 
 
2 
a) On the reference date, main reason for no HCV-treatment despite pos. HCV-RNA: 
(1 = reimbursement restrictions, 2 = non-compliance with appointments, 3 = patient not motivated 
enough, 4 = uncontrolled substance use, 5 = uncontrolled alcohol use, 6 = uncontrolled psychiatric 
disorder, 7 = uncontrolled somatic disease, 8 = unstable life situation, 9 = other) 
 
 Main reason for 
no HCV-treatment 
if other(9), specify 
1.5.2017   
1.5.2018   




b) All HCV-treatments in chronological order: from when until when, with what, 
(IFN (interferon): 0 = no, 1 = interferon-alpha, 2 = pegylated interferon; 
RBV (ribavirin): 0 = no, 1 = yes, 9 = unknown; 
DAA (direct-acting antivirals)/other: 0 = no, 1 = Incivo (telaprevir), 2 = Victrelis (boceprevir), 3 = 
Sovaldi (sofosbuvir), 4 = Harvoni (ledipasvir/sofosbuvir), 5 = Viekirax/Exviera 
(ombitasvir/paritaprevir/ritonavir/dasabuvir), 6 = Viekirax (ombitasvir/paritaprevir/ritonavir), 7 = 
Daklinza/Sovaldi (daclatasvir/sofosbuvir), 8 =Zepatier (grazoprevir/elbasvir), 9 = Epclusa 
(velpatasvir/sofosbuvir), 10 = Maviret (glecaprevir/pibrentasvir), 11 = Vosevi 
(sofosbuvir/velpatasvir/voxilaprevir), 12 = other (specify under comments), 99 = unknown) 
HCV-genotype (gt), 
(Num. (number): 1-7, 9 = unknown; Let. (letter): 1 = a, 2 = b, 3 = c, 4 = d, 5 = multiple subtypes, 9 
= subtype not defined) 
and outcome 
(0 = ongoing treatment, 1 = SVR (sustained virological response), 2 = EOT (end of treatment 
response; if HCV-treatment is completed, but SVR not yet determined), 3 = relapse, 4 = viral 
breakthrough, 5 = non-response, 6 = PTS (pre-term stop)), 9 = unknown; 
Why PTS: 1 = toxicity/complication related to HCV-treatment, 2 = medical complication not related 
to hepatitis C treatment, 3 = patient’s wish, 4 = loss to follow-up, 5 = death, 6 = other (specify 






Medication HCV-gt Out- 
come 
Why 
PTS IFN RBV DAA/other Num. Let. 
1st          
2nd          
3rd          
4th          




c) What about adherence during HCV-treatments (in chronological order)? 
DOT = Directly observed therapy 





in pill box* 
Adherence# 
1st    
2nd    
3rd    
4th    
5th    
 
Comments: ____________________________________________________________________ 
SAMMSU-ID: ____________________ (please insert on all pages) 
 
3 
d) Current liver fibrosis stage (last available result: 1.5.2017 (I), 1.5.2018 (II) and 1.5.2019 (III)); 
if HCV-treatment, additionally results before (B) and after (A) 1st, 2nd, 3rd, … treatment 
(The same examination might appear more than once.) 
 


















(I)        
(II)        
(III)        
B 1st        
A 1st        
B 2nd        
A 2nd        
B 3rd        
A 3rd        
B 4th        
A 4th        
B 5th        
A 5th        
 
3) On the reference date, has the patient ever experienced HCV-reinfection? 
*(0 = no, 1 = yes) 
#(After: 1 = spontaneous clearance, 2 = successful treatment) 
§(1 = unsafe intravenous drug use, 2 = unsafe intranasal drug use, 3 = unsafe anal intercourse, 4 = 
other (specify under comments), 9 = unknown) 
$(Outcome: 1 = spontaneous clearance, 2 = chronic infection, 9 = unknown) 
 
 Ever HCV- 
Reinfection* 
  Diagnosis of 
HCV-reinfection 
(DD/MM/YYYY) 






1.5.2017  1st     
1.5.2018  2nd     




4) Drug use on the reference date 
*(Ever: 0 = no, 1 = yes, 9 = unknown) 
#(Cont. (continued): 0 = no (last use >12 months ago), 1 = yes (last use ≤12 months ago), 9 = 
unknown) 
 
 intravenous intranasal 
Ever* Cont.# Ever* Cont.# 
1.5.2017     
1.5.2018     
1.5.2019     
 
a) first year of intravenous drug use: ________ (YYYY) 
 
b) first year of intranasal drug use: ________ (YYYY) 




5) Please enter all available HCV-RNA-values into the SAMMSU-database! 
 




Cross sectional study 
01.05.2018 
Cross sectional study 
01.05.2019 
Last contact with the patient 
(DD/MM/YYYY) 
  
Completed by:   
Date:   
 
Please note: 
For patients recruited after the 01/05/2018, please complete the whole questionnaire, i.e. 
both cross sectional studies (01/05/2018 and 01/05/2019) in 2019. 
SAMMSU-Centre: ____________________ (please insert on all pages) 
1 
Centre-Questionnaire – Cross sectional study within SAMMSU May 2018 and May 2019 
Main form 
1) On the reference date, how was your centre organised?
*(1 = specialised opioid substitution centre with integrated somatic care, 2 = specialised opioid 
substitution centre without integrated somatic care, 3 = private practice, 4 = decentralised setting, 5 



















3) Please fill in and attach a separate form (page 2-4) for each of the institutions/sites!
Thank you very much! 
Cross sectional study 
01.05.2018 





For centres/institutions/sites recruited after the 01/05/2018, please complete the whole 
questionnaire, i.e. both cross sectional studies (01/05/2018 and 01/05/2019) in 2019. 
SAMMSU-Centre: ____________________ (please insert on all pages) 
 
2 
Centre-Questionnaire – Cross sectional study within SAMMSU May 2018 and May 2019 
Institution/Site: ____________________ 
 
1) Does this institution/site provide substitution treatment? 
(0 = no, 1 = yes) 
 
1.5.2017 1.5.2018 1.5.2019 
   
 
a) if yes, number of patients receiving their substitution directly in the institution/site: ____ 
               number of patients receiving their substitution in a pharmacy: ____ 
 
b) if yes, which substitution treatments are provided? 
(0= no, 1 = yes, 9 = unknown) 
 
 Heroin Methadone 
(incl. levo-
methadone) 
Buprenorphine Sevre-Long Diazepam Other* 
1.5.2017       
1.5.2018       
1.5.2019       
 
*if other, specify: _______________________________________________________________ 
 










the end of the 
past year (e.g. 
1.5.2017 → 
end of 2016) 
Number of newly 
admitted patients 








1.5.2017      
1.5.2018      
1.5.2019      
 
2) Please provide the HCV treatment cascade of this institution/site: 
 
 1.5.2017 1.5.2018 1.5.2019 
Total number of 
substitution patients 
   
   - HCV-antibody-tested    
HCV-antibody-positives    
   - HCV-RNA-tested    
Ever chronically HCV-
infected 
   
   - HCV-genotype known    
   - liver biopsy performed    
   - fibroscan performed    
   - ever treated for HCV    
   - cured (SVR, Sustained 
virological response) 
   
Number of patients 
enrolled into SAMMSU 
   
 







3) How is the institution/site regularly equipped? 
(0 = no, 1 = yes) 
 
 1.5.2017 1.5.2018 1.5.2019 
Capillary blood examination (hematology/chemistry)    
Venous blood draw on site    
Centrifuge    
HCV rapid tests    
HIV rapid tests    
Capillary HCV-RNA (Dried blood spot)    
Capillary HCV-RNA (GeneXpert)    
Sonography    
Fibroscan    
Liver biopsy    
Prescription of HCV therapy on site    




4) How is the institution/site regularly staffed? 
(n = number of individuals, FTE = full-time equivalents [1 FTE = 100% position]) 
 
 1.5.2017 1.5.2018 1.5.2019 
n FTE n FTE n FTE 
Social workers       
Addiction specialists       
Psychiatrists       
Somatic physicians       
Infectious disease specialists       
Hepatologists       
Study nurses       
Technical and clinical assistants 
(e.g. MPA, clinical nurse) 
      




5) To whom does the institution/site regularly refer patients for the following: 
(multiple answers allowed, please start with highest priority and separate by comma) 
(0 = no referral, done within the institution/site, 1 = infectious disease specialist in hospital, 2 = 
hepatologist in hospital, 3 = infectious disease specialist in private practice, 4 = hepatologist in 
private practice, 5 = general practitioner, 6 = other (specify under comments) 
 
 1.5.2017 1.5.2018 1.5.2019 
Sonography    
Fibroscan    
Liver biopsy    
HCV treatment    
Somatic problems    
 
Comments: ____________________________________________________________________ 





6) Does this institution/site perform hepatitis C action days? 
(0 = no, 1 = yes) 
 
1.5.2017 1.5.2018 1.5.2019 
   
 
a) if yes, how many hepatitis C action days did the institution/site perform in the past year? 
(e.g. 1.5.17 → 2016) 
 
1.5.2017 1.5.2018 1.5.2019 




b) if yes, what was offered? 
(0 = no, 1 = yes) 
 
 1.5.2017 1.5.2018 1.5.2019 
HCV rapid test (capillary blood)    
HCV rapid test (saliva)    
HIV rapid test    
Capillary HCV-RNA (Dried blood spot)    
Capillary HCV-RNA (GeneXpert)    
Venous blood draw    
Hepatitis B serology    
Hepatitis A serology    
Hepatitis B vaccination    
Hepatitis A vaccination    
Sonography    
Fibroscan    
Prescription of HCV therapy (Test and treat)    
Referral to HCV therapy prescriber    
Other (1), specify:    
Other (2), specify:    
Other (3), specify:    
Other (4), specify:    




c) if yes, how were the events staffed? 
(n= number of individuals) (DAAs = Direct-acting antivirals) 
 
 1.5.2017 1.5.2018 1.5.2019 
n n n 
Nurses    
Physicians    
Addiction specialists authorised 
to prescribe HCV therapy (DAAs) 
   
Infectious disease specialists    
Hepatologists    
 
